Effective Date: 11/13/18 Date Reviewed/ Date Revised: 11/13/18

# LOOKBACK FOR TRANSFUSION TRANSMITTED DISEASES AND MARKET WITHDRAWALS

### I. PRINCIPLE:

In keeping with FDA requirements and the American Association of Blood Banks, our blood supplier, American Red Cross Heart of America Region, will notify us of any blood component shipped to us in the past where a donor has been subsequently found to be positive for HIV, HTLV I/II, Hbs/Ag, HCV, or other required disease markers. The ARC will also notify us if any blood component is to be recalled/withdrawn from the general inventory for another reason. Our hospital/blood bank has the responsibility to notify the involved parties for necessary follow-up.

### II. POLICY STATEMENT:

All information about lookback patients and test results will be kept confidential. The responsibility to notify the patient rests with the attending physician. A good-faith effort will be made to get this information to the patient. Neither the blood bank medical director nor other hospital employees will contact the patient unless all attempts to reach the physician have failed.

### III. PROCEDURE:

- A. The ARC Medical Director will notify our Blood Bank Supervisor in writing that the implicated unit was shipped to UnityPoint Health-Pekin Hospital. The unit number(s), blood component type, and shipping date will be specified.
- B. Upon receipt of the letter, the inventory will be searched for the implicated unit(s) to determine the disposition of the unit(s). Use Blood Bank Inquiry (BIQ) for any unit shipped after 9/15/18. Records for units received prior to this date shall be searched manually in the Blood Bank Inventory Registers (located in the upper cabinets in the back of Blood Bank). If in inventory it will be immediately placed in a biohazard bag, marked quarantined, and sequestered on the bottom shelf of the Blood Bank refrigerator until notification is received from ARC as to the final disposition.
- C. If the unit has been transfused, the Blood Bank Supervisor will search for the patient who received the implicated unit(s) and print out the patient's information from the LIS. Complete the requested information on the ARC form and fax back to ARC. The supervisor will then give the information to the Blood Bank Medical Director or designee.
- D. The Blood Bank Medical Director will notify by letter the current attending physician involved in treating the patient when appropriate.
- E. The blood supplier will, in some cases, offer the implicated disease markers testing free of charge to the lookback patient. Specimens for look back testing

Section: UPPK BB-0530

UnityPoint Health Pekin Department of Pathology Pekin, IL 61554 Effective Date: 11/13/18
Date Reviewed/ Date Revised: 11/13/18

- should be drawn in the physician's office or the hospital laboratory and brought directly to the blood bank. The blood bank staff will send the specimen to the ARC testing laboratory.
- F. When received from ARC, the test results will be sent to the current attending physician of the patient.
- G. When possible or necessary, ARC will provide information about patient management and/or referral for counseling. The blood bank will forward any pertinent information to the physician.
- H. Copies of these reports will be kept within the laboratory.
- I. Notes:
  - If neither the current attending physician nor the physician who ordered the identified blood transfusion is willing or able to notify the traced recipient, the UnityPoint Health-Pekin Hospital Infection Control Coordinator shall be involved in contacting the patient.
  - All steps taken in implementing the notification of traced recipients or their spouses, including instances in which the traced recipient cannot be located by the UnityPoint Health Pekin Hospital Blood Bank or appropriate physician, shall be documented in writing and kept on file.

### IV. REFERENCES

- A. AABB Technical Manual, 19<sup>th</sup> Edition, P. 457-458, American Association of Blood Banks, Bethesda, MD, 2017.
- B. Standards for Blood Banks and Transfusion Services: AABB, Arlington, VA; 29th ed., 2014.

<b>POLICY CREATION:</b>		Date			
Author: Sharrol E	Brisbin, MT (ASCP)	01/01/1999			
Medical Director: K	athryn Kramer, MD	01/01/1999			
The State of the S	MEDICAL DIRI	ECTOR			
DATE	NAME	SIGNATURE			
124-16	Kathela O. Koroma MD				
	SECTION MEDICAL	DIRECTOR			

Section: UPPK BB-0530

Effective Date: 11/13/18 Date Reviewed/ Date Revised: 11/13/18

REVISION HISTORY (began tracking 2011)						
Rev	Description of Change	Author	Effective Date			
11/13/18	UPH format and update references	Jenny Turner	11/13/18			

## Reviewed by

Lead	Date	Coordinator/ Manager	Date	Medical Director	Date
Jante Lune	12-3-18				

Section: UPPK BB-0530